002550 千红制药
已收盘 12-12 15:00:00
资讯
新帖
简况
千红制药（002550）披露调整向不特定对象发行可转换公司债券方案，12月10日股价上涨0.25%
证券之星 · 12-10
千红制药（002550）披露调整向不特定对象发行可转换公司债券方案，12月10日股价上涨0.25%
千红制药：创新药项目正有序推进临床试验
证券之星 · 12-02
千红制药：创新药项目正有序推进临床试验
千红制药：暂未收到大股东减持计划
证券之星 · 11-26
千红制药：暂未收到大股东减持计划
千红制药：11月21日高管赵刚减持股份合计142.95万股
证券之星 · 11-24
千红制药：11月21日高管赵刚减持股份合计142.95万股
千红制药：11月20日高管赵刚减持股份合计461.8万股
证券之星 · 11-21
千红制药：11月20日高管赵刚减持股份合计461.8万股
千红制药（002550）披露实施2025年员工持股计划，11月11日股价上涨0.11%
证券之星 · 11-11
千红制药（002550）披露实施2025年员工持股计划，11月11日股价上涨0.11%
股市必读：千红制药（002550）11月7日董秘有最新回复
证券之星 · 11-10
股市必读：千红制药（002550）11月7日董秘有最新回复
千红制药：尚未收到股东减持进展通知
证券之星 · 11-07
千红制药：尚未收到股东减持进展通知
千红制药（002550）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 10-31
千红制药（002550）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
千红制药：湖北原料药基地正紧锣密鼓建设中
证券之星 · 10-30
千红制药：湖北原料药基地正紧锣密鼓建设中
图解千红制药三季报：第三季度单季净利润同比下降1.28%
证券之星 · 10-30
图解千红制药三季报：第三季度单季净利润同比下降1.28%
千红制药：尚未收到股东减持进展通知
证券之星 · 10-14
千红制药：尚未收到股东减持进展通知
千红制药：创新药项目按计划推进临床试验
证券之星 · 09-22
千红制药：创新药项目按计划推进临床试验
千红制药：氢溴酸替格列汀片处于补充药学资料持续审评过程中
证券之星 · 09-17
千红制药：氢溴酸替格列汀片处于补充药学资料持续审评过程中
股市必读：千红制药（002550）9月12日董秘有最新回复
证券之星 · 09-15
股市必读：千红制药（002550）9月12日董秘有最新回复
千红制药：创新药项目QHRD106、QHRD107按计划有序推进临床试验
证券之星 · 09-12
千红制药：创新药项目QHRD106、QHRD107按计划有序推进临床试验
千红制药：总经理王轲因未及时披露公司重大事件等违规行为被深圳证券交易所采取监管措施
证券之星 · 09-11
千红制药：总经理王轲因未及时披露公司重大事件等违规行为被深圳证券交易所采取监管措施
千红制药：创新药项目QHRD107、QHRD106、QHRD110等多只新药处于二期临床试验或即将进入三期临床阶段
证券之星 · 09-02
千红制药：创新药项目QHRD107、QHRD106、QHRD110等多只新药处于二期临床试验或即将进入三期临床阶段
股市必读：千红制药中报 - 第二季度单季净利润同比增长23.38%
证券之星 · 08-25
股市必读：千红制药中报 - 第二季度单季净利润同比增长23.38%
千红制药(002550.SZ)发布上半年业绩，归母净利润2.58亿元，增长41.17%
智通财经 · 08-22
千红制药(002550.SZ)发布上半年业绩，归母净利润2.58亿元，增长41.17%
暂无数据
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是药物研发、生产和应用。公司的主要产品是胰激肽原酶系列、复方消化酶胶囊（Ⅱ）、门冬酰胺酶系列和弹性酶、肝素钠及低分子肝素类系列。公司是国家级高新技术企业。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":8.01,"timestamp":1765522992000,"preClose":8,"halted":0,"volume":12359800,"delay":0,"changeRate":0.0012,"floatShares":941000000,"shares":1280000000,"eps":0.3358,"marketStatus":"已收盘","change":0.01,"latestTime":"12-12 15:00:00","open":8.01,"high":8.05,"low":7.93,"amount":98997000,"amplitude":0.015,"askPrice":8.02,"askSize":226,"bidPrice":8.01,"bidSize":938,"shortable":0,"etf":0,"ttmEps":0.3358,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":8,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":8.8,"lowLimit":7.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":3.72,"roa":"--","peRate":23.853484,"roe":"14.5%","epsLYR":0.28,"committee":0.075015,"marketValue":10251000000,"turnoverRate":0.0131,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-15。","floatMarketCap":7539000000},"requestUrl":"/m/hq/s/002550/tweets","defaultTab":"tweets","newsList":[{"id":"2590353898","title":"千红制药（002550）披露调整向不特定对象发行可转换公司债券方案，12月10日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590353898","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590353898?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:08","pubTimestamp":1765375693,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，千红制药报收于8.07元，较前一交易日上涨0.25%，最新总市值为103.28亿元。近日，千红制药发布公告称，公司于2025年12月10日召开2025年第二次临时股东会，会议审议通过了关于调整公司向不特定对象发行可转换公司债券方案的议案。公告显示，此次股东大会出席会议的股东共548人，代表股份501,287,280股，占公司有表决权股份总数的40.1094%。包括本次调整方案在内的七项相关议案均获得出席股东所持有效表决权三分之二以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"gpt_icon":0},{"id":"2588874440","title":"千红制药：创新药项目正有序推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2588874440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588874440?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:09","pubTimestamp":1764659356,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:公司过几天就召开股东大会为创新药募资发债投票表决了，是不是应该公布106/107这两个创新药的期临床数据给持股的投资者看看和评估？千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107目前均处于有序推进临床试验的过程中，相关进展将严格遵循法规披露要求，公司将在定期报告及相关公告中及时披露重大研发进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200016948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK1574","BK0239","BK1161","06978","159992"],"gpt_icon":0},{"id":"2586523002","title":"千红制药：暂未收到大股东减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2586523002","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586523002?lang=zh_cn&edition=full","pubTime":"2025-11-26 20:52","pubTimestamp":1764161538,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：大股东的减持，对股票的波动造成很大的影响。请问大股东减持结束后，要过多长时间才能继续减持？千红制药回复：尊敬的投资者，您好，目前公司暂未收到大股东的减持计划，后续如公司收到大股东的减持告知函，将按证监会、深交所相关规定履行信息披露义务。感谢您对公司的关注，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600035808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2585462148","title":"千红制药：11月21日高管赵刚减持股份合计142.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462148","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585462148?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:01","pubTimestamp":1763989305,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月24日市场公开信息、上市公司公告及交易所披露数据整理，千红制药（002550）最新董监高及相关人员股份变动情况：2025年11月21日公司董事赵刚共减持公司股份142.95万股，占公司总股本为0.1117%。变动期间公司股价下跌3.28%，11月21日当日收盘报8.25元。千红制药近半年内的董监高及核心技术人员增减持详情如下：千红制药的高管列表及最新持股情况如下：该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400032840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"gpt_icon":0},{"id":"2585908143","title":"千红制药：11月20日高管赵刚减持股份合计461.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585908143","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585908143?lang=zh_cn&edition=full","pubTime":"2025-11-21 21:02","pubTimestamp":1763730129,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月21日市场公开信息、上市公司公告及交易所披露数据整理，千红制药（002550）最新董监高及相关人员股份变动情况：2025年11月20日公司董事赵刚共减持公司股份461.8万股，占公司总股本为0.3608%。变动期间公司股价下跌0.12%，11月20日当日收盘报8.53元。千红制药近半年内的董监高及核心技术人员增减持详情如下：千红制药的高管列表及最新持股情况如下：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100037388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2582592367","title":"千红制药（002550）披露实施2025年员工持股计划，11月11日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582592367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582592367?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:27","pubTimestamp":1762871244,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，千红制药报收于9.19元，较前一交易日上涨0.11%，最新总市值为117.61亿元。近日，千红制药发布关于实施2025年员工持股计划的相关公告。本次员工持股计划参加对象不超过60人，资金来源为员工自筹，股票来源为公司回购股份，存续期不超过48个月，遵循自愿参与、风险自担原则，不涉及财务资助或一致行动安排。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100040929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2582474818","title":"股市必读：千红制药（002550）11月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582474818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582474818?lang=zh_cn&edition=full","pubTime":"2025-11-10 02:17","pubTimestamp":1762712232,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，千红制药报收于9.09元，上涨0.33%，换手率2.04%，成交量19.19万手，成交额1.74亿元。董秘最新回复投资者： 董秘，您好！大股东赵刚公布减持股份已进入第3个月，请公布其目前已实施减持的股份数量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"gpt_icon":0},{"id":"2581888886","title":"千红制药：尚未收到股东减持进展通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888886","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581888886?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:48","pubTimestamp":1762519735,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)11月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！大股东赵刚公布减持股份已进入第3个月，请公布其目前已实施减持的股份数量。千红制药回复：尊敬的投资者，您好，根据公司已披露的减持预披露公告（公告编号：2025-021），赵刚先生及其一致行动人减持计划将根据市场情况、公司股价等综合因素决定是否实施。截至目前，公司尚未收到该股东的减持进展通知，后续将严格履行信息披露义务。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700036456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"gpt_icon":0},{"id":"2579101648","title":"千红制药（002550）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101648?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:43","pubTimestamp":1761864230,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期千红制药发布2025年三季报。截至本报告期末，公司营业总收入12.15亿元，同比上升0.61%，归母净利润3.83亿元，同比上升23.79%。按单季度数据看，第三季度营业总收入3.53亿元，同比上升0.35%，第三季度归母净利润1.25亿元，同比下降1.28%。本报告期千红制药盈利能力上升，毛利率同比增幅6.84%，净利率同比增幅22.54%。持有千红制药最多的基金为博道中证1000指数增强A，目前规模为1.47亿元，最新净值1.5421，较上一交易日下跌1.43%，近一年上涨53.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"gpt_icon":0},{"id":"2579151130","title":"千红制药：湖北原料药基地正紧锣密鼓建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2579151130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579151130?lang=zh_cn&edition=full","pubTime":"2025-10-30 08:42","pubTimestamp":1761784933,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问千红湖北项目建设现在进展到什么程度了？预计什么时候投入生产？千红制药回复：尊敬的投资者，您好，公司千红湖北原料药生产基地项目目前正在紧锣密鼓地建设过程中，公司正紧抓湖北千红等上游原料端战略投资项目的投产进程，争取早日实现投产。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000009493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2579841180","title":"图解千红制药三季报：第三季度单季净利润同比下降1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579841180","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579841180?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:18","pubTimestamp":1761765513,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药2025年三季报显示，前三季度公司主营收入12.15亿元，同比上升0.61%；归母净利润3.83亿元，同比上升23.79%；扣非净利润2.71亿元，同比上升18.76%；其中2025年第三季度，公司单季度主营收入3.53亿元，同比上升0.35%；单季度归母净利润1.25亿元，同比下降1.28%；单季度扣非净利润7236.35万元，同比上升48.35%；负债率8.48%，投资收益950.05万元，财务费用-20.27万元，毛利率57.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"gpt_icon":0},{"id":"2575921368","title":"千红制药：尚未收到股东减持进展通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2575921368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575921368?lang=zh_cn&edition=full","pubTime":"2025-10-14 20:53","pubTimestamp":1760446401,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药10月14日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，根据公司2025年8月7日披露的减持预披露公告，赵刚先生及其一致行动人的减持计划将根据市场情况、公司股价等因素决定是否实施。截至目前，公司尚未收到该股东减持进展通知，后续将严格履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400062445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2569099812","title":"千红制药：创新药项目按计划推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2569099812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569099812?lang=zh_cn&edition=full","pubTime":"2025-09-22 15:07","pubTimestamp":1758524837,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药09月22日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注国家创新药政策导向，全力推进创新药研发进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200014036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002550","06978","159992","BK1161","BK0239"],"gpt_icon":0},{"id":"2568147459","title":"千红制药：氢溴酸替格列汀片处于补充药学资料持续审评过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2568147459","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568147459?lang=zh_cn&edition=full","pubTime":"2025-09-17 11:38","pubTimestamp":1758080314,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药09月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，据了解公司仿制药氢溴酸替格列汀片已于9月12日完成审评，然公司未就此发布任何公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700017342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"gpt_icon":0},{"id":"2567157279","title":"股市必读：千红制药（002550）9月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567157279","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567157279?lang=zh_cn&edition=full","pubTime":"2025-09-15 04:11","pubTimestamp":1757880672,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，千红制药报收于10.07元，上涨0.8%，换手率2.46%，成交量23.18万手，成交额2.32亿元。董秘最新回复投资者： 董秘你好！根据CDE官网显示，公司核心创新药106和107目前处于“已反馈”状态。想了解一下贵公司创新药QHRD106和QHRD107的最新审评进度。当日关注点来自交易信息汇总：9月12日主力资金净流出383.61万元，散户资金净流入562.46万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"gpt_icon":0},{"id":"2566944086","title":"千红制药：创新药项目QHRD106、QHRD107按计划有序推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2566944086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566944086?lang=zh_cn&edition=full","pubTime":"2025-09-12 11:34","pubTimestamp":1757648044,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药09月12日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司董事会、经营管理机构将共同致力于推动公司创新发展，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。公司将严格遵循法规披露要求，感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200014012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","06978","159992","002550","BK1574"],"gpt_icon":0},{"id":"2566676059","title":"千红制药：总经理王轲因未及时披露公司重大事件等违规行为被深圳证券交易所采取监管措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2566676059","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566676059?lang=zh_cn&edition=full","pubTime":"2025-09-11 19:01","pubTimestamp":1757588461,"startTime":"0","endTime":"0","summary":"证券之星消息，9月11日千红制药公开信息显示，总经理王轲因未及时披露公司重大事件,违规交易被深圳证券交易所上市公司管理二部采取监管措施。你在与一致行动人王耀方合计持股比例达到25%时,未能按照《上市公司收购管理办法》的相关规定停止买入上市公司股份并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100032647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","399001","002550"],"gpt_icon":0},{"id":"2564802827","title":"千红制药：创新药项目QHRD107、QHRD106、QHRD110等多只新药处于二期临床试验或即将进入三期临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2564802827","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564802827?lang=zh_cn&edition=full","pubTime":"2025-09-02 11:38","pubTimestamp":1756784289,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药09月02日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司的创新药项目QHRD107、QHRD106、QHRD110均为公司自主研发的原创一类新药，历经研发团队多年精耕细作，目前QHRD107、QHRD106、QHRD110等多只新药正处于二期临床试验或即将进入三期临床阶段，还有数只创新药处于一期临床试验或待批进入临床研究阶段，具体信息烦请详见公司发布的定期报告。公司始终坚持创新驱动战略，相关进展将严格遵循法规披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200015493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002550","06978","159992","BK1161","BK0239"],"gpt_icon":0},{"id":"2562269178","title":"股市必读：千红制药中报 - 第二季度单季净利润同比增长23.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562269178","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562269178?lang=zh_cn&edition=full","pubTime":"2025-08-25 01:07","pubTimestamp":1756055231,"startTime":"0","endTime":"0","summary":"股本股东变化：截至2025年6月30日，千红制药股东户数增至7.28万户，较3月底增加1.55万户，增幅达27.0%。业绩披露要点：千红制药2025年上半年实现归母净利润2.58亿元，同比增长41.17%，其中二季度单季归母净利润为9708.21万元，同比增长23.38%。其中，2025年第二季度，公司单季度主营收入为4.11亿元，同比上升4.16%；单季度归母净利润为9708.21万元，同比上升23.38%；单季度扣非净利润为9176.28万元，同比上升18.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500000481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"gpt_icon":0},{"id":"2561042038","title":"千红制药(002550.SZ)发布上半年业绩，归母净利润2.58亿元，增长41.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561042038","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561042038?lang=zh_cn&edition=full","pubTime":"2025-08-22 17:38","pubTimestamp":1755855481,"startTime":"0","endTime":"0","summary":"智通财经APP讯，千红制药(002550.SZ)发布2025年半年度报告，该公司营业收入为8.62亿元，同比增长0.72%。归属于上市公司股东的净利润为2.58亿元，同比增长41.17%。归属于上市公司股东的扣除非经常性损益的净利润为1.99亿元，同比增长10.71%。基本每股收益为0.2065元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"千红制药(002550.SZ)发布上半年业绩，归母净利润2.58亿元，增长41.17%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002550"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765669543135,"stockEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":-0.1198},{"period":"3month","weight":-0.2054},{"period":"6month","weight":-0.217},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.3138}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"73615人(较上一季度增加1.17%)","perCapita":"12785股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是药物研发、生产和应用。公司的主要产品是胰激肽原酶系列、复方消化酶胶囊（Ⅱ）、门冬酰胺酶系列和弹性酶、肝素钠及低分子肝素类系列。公司是国家级高新技术企业。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}